Efficacy of Biologics in Patients with Moderate to Very Severe COPD: A Systematic Review.

Tezspire (tezepelumab-ekko) - AstraZeneca, Amgen

Nucala (mepolizumab) - GSK

astegolimab (RG6149) - Roche

tozorakimab (MEDI3506) - AstraZeneca

itepekimab (SAR440340) - Sanofi, Regeneron

Fasenra (benralizumab) - AstraZeneca

Dupixent (dupilumab) - Sanofi, Regeneron

http://www.ncbi.nlm.nih.gov/pubmed/42741717

Amit D Parulekar; Christopher E Brightling; Dave Singh; Elizabeth A Gandhi; Jean Bourbeau; Klaus F Rabe; M Bradley Drummond; MeiLan K Han; Mohit Bhutani; Navreet S Sindhwani; Nestor A Molfino; Parameswaran Nair; Sandhia S Ponnarambil

Sep 16, 2026